Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

E2012-Induced Cataract and Its Predictive Biomarkers

(2013) K. Nakano-Ito et al.   TOXICOLOGICAL SCIENCES

Alzheimer's Disease: Critical Notes on the History of a Medical Concept

(2012) Jesus Ramirez-Bermudez   ARCHIVES OF MEDICAL RESEARCH

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity

(2012) Christina J. Crump et al.   BIOCHEMISTRY

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers

(2012) Gary Tong et al.   CLINICAL THERAPEUTICS

First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms

(2012) Tomas Borgegard et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

(2011) Bruno P Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

γ-Secretase inhibitors and modulators for Alzheimer’s disease

(2011) Michael S. Wolfe   JOURNAL OF NEUROCHEMISTRY

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein  -Secretase for the Treatment of Alzheimer's Disease

(2009) R. L. Martone et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Signal peptide peptidases: A family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins

(2009) Todd E. Golde et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Disease-modifying therapies in Alzheimer’s disease

(2008) Stephen Salloway et al.   Alzheimers & Dementia

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

Current and future therapy in Alzheimer’s disease

(2008) Robert J. van Marum   FUNDAMENTAL & CLINICAL PHARMACOLOGY

The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression

(2008) Catherine R. Burton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The molecular logic of Notch signaling - a structural and biochemical perspective

(2008) W. R. Gordon et al.   JOURNAL OF CELL SCIENCE

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

Mixed results for disease-modification strategies for Alzheimer's disease

(2008) Alisa Opar   NATURE REVIEWS DRUG DISCOVERY

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

(2003) H. F. Dovey et al.   JOURNAL OF NEUROCHEMISTRY